Musa Yilmaz, MD
Hematology & Oncology · Houston, TXNPI 1538505656
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,703 of the $11,808 with a category attached, or 90.6%. Daiichi Sankyo Inc. accounts for 64.6% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $7,521 and has fallen 91.1% since, to $668 in 2024.
Across 18 payments — averaging $655.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$8K
- AstraZeneca$4K
- Pfizer$242
- Astellas Pharma US Inc$141
- Pharmaessentia USA Corporation$40
- Lilly USA, LLC$33
- plus $105 from 4 others
Across 15 payments — averaging $69,020 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1M
- Institut DE Recherches Internationales Servier$22K
What the payments were for
- Consulting fees$10,70391%
- Speaking & faculty fees$3603%
- Food & beverage$7456%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 6 | $7,626 |
| AstraZeneca | 3 | $3,621 |
| Pfizer | 2 | $242 |
| Astellas Pharma US Inc | 1 | $141 |
| Pharmaessentia USA Corporation | 1 | $40 |
| Lilly USA, LLC | 1 | $33 |
| GSK | 1 | $28 |
| Sobi, Inc | 1 | $27 |
| Bristol Myers Squibb | 1 | $26 |
| Novartis | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,808 in reported general payments places this provider in the 70th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VenclextaVenetoclax | 54 | $262,050 |
| ValacyclovirValacyclovir Hcl | 33 | $468 |
| Levofloxacin | 27 | $433 |
| Rosuvastatin Calcium | 11 | $60 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Houston
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Naval DaverHouston$853K
- Jorge Cortes-FrancoHouston$627K
- Courtney DinardoHouston$478K
- Prithviraj BoseHouston$463K
- Milind JavleHouston$326K
- Loretta NastoupilHouston$309K
- Boyu HuHouston$281K
- Luis CamachoHouston$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.